Selected article for: "adaptive immunity and mouse strain"
Author: Gawish, Riem; Starkl, Philipp; Pimenov, Lisabeth; Hladik, Anastasiya; Lakovits, Karin; Oberndorfer, Felicitas; Cronin, Shane J.F.; Ohradanova-Repic, Anna; Wirnsberger, Gerald; Agerer, Benedikt; Endler, Lukas; Capraz, Tümay; Perthold, Jan W.; Hagelkruys, Astrid; Montserrat, Nuria; Mirazimi, Ali; Boon, Louis; Stockinger, Hannes; Bergthaler, Andreas; Oostenbrink, Chris; Penninger, Josef M.; Knapp, Sylvia
Title: ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
  • Cord-id: 49785iij
  • Document date: 2021_8_9
    • ID: 49785iij
    Snippet: Despite tremendous progress in the understanding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited. We generated maVie16, a mouse-adapted SARS-CoV-2, by serial passaging of a human isolate. In silico modelling revealed how Spike mutations of maVie16 enhanced interaction with murine ACE2. MaVie16 induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early
    Document: Despite tremendous progress in the understanding of COVID-19, mechanistic insight into immunological, disease-driving factors remains limited. We generated maVie16, a mouse-adapted SARS-CoV-2, by serial passaging of a human isolate. In silico modelling revealed how Spike mutations of maVie16 enhanced interaction with murine ACE2. MaVie16 induced profound pathology in BALB/c and C57BL/6 mice and the resulting mouse COVID-19 (mCOVID-19) replicated critical aspects of human disease, including early lymphopenia, pulmonary immune cell infiltration, pneumonia and specific adaptive immunity. Inhibition of the proinflammatory cytokines IFNγ and TNF substantially reduced immunopathology. Importantly, genetic ACE2-deficiency completely prevented mCOVID-19 development. Finally, inhalation therapy with recombinant ACE2 fully protected mice from mCOVID-19, revealing a novel and efficient treatment. Thus, we here present maVie16 as a new tool to model COVID-19 for the discovery of new therapies and show that disease severity is determined by cytokine-driven immunopathology and critically dependent on ACE2 in vivo. Key points The mouse-adapted SARS-CoV-2 strain maVie16 causes fatal disease in BALB/c mice and substantial inflammation, pneumonia and immunity in C57BL/6 mice TNFα/IFNγ blockade ameliorates maVie16-induced immunopathology MaVie16 infection depends on ACE2 and soluble ACE2 inhalation can prevent disease

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and additional evidence: 1, 2, 3
    • acute ards respiratory distress syndrome and additional receptor: 1
    • acute ards respiratory distress syndrome and low infection dose: 1
    • acute ards respiratory distress syndrome and low lung weight: 1, 2
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lung accumulate: 1, 2
    • acute ards respiratory distress syndrome and lung blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and additional evidence: 1, 2, 3, 4, 5
    • acute infection and additional mutation: 1
    • acute infection and additional receptor: 1, 2, 3, 4, 5, 6
    • acute infection and low infection dose: 1, 2, 3, 4, 5
    • acute infection and low respiratory tract: 1, 2, 3, 4, 5, 6, 7
    • acute infection and lung blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute infection and lung cell composition: 1
    • acute infection and lung expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adaptive immunity and additional receptor: 1, 2
    • adaptive immunity and lung expression: 1, 2, 3, 4, 5, 6, 7